Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- Michael E DeBakey VA Medical Center — Houston, Texas
- UT MD Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Texas: - Research Site — Dallas, Texas
- Research Site — Dallas, Texas
- Research Site — Sherman, Texas
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in Texas: - Site 22 — Austin, Texas
- Site 1 — Houston, Texas
- Site 18 — Plano, Texas
- Site 17 — Sugar Land, Texas
- Site 15 — Tyler, Texas
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Texas: - GSK Investigational Site — Dallas, Texas
- GSK Investigational Site — Fort Worth, Texas
- GSK Investigational Site — San Antonio, Texas
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- Oncology Consultants — Houston, Texas
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in Texas: - UT MD Anderson - The Woodlands — Conroe, Texas
- UT MD Anderson Cancer Center — Houston, Texas
- UT MD Anderson - West Houston — Houston, Texas
- UT MD Anderson - League City — League City, Texas
- UT MD Anderson - Sugar Land — Sugar Land, Texas
Phase 3 Recruiting Industry
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…
Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in Texas: - Research Site — Dallas, Texas
- Research Site — Fort Worth, Texas
- Research Site — Houston, Texas
- Research Site — Tyler, Texas
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Texas: - Texas Oncology - DFW ( Site 8005) — Fort Worth, Texas
- Texas Oncology-The Woodlands ( Site 8000) — The Woodlands, Texas
- Texas Oncology - Northeast Texas ( Site 8002) — Tyler, Texas
Phase 2, Phase 3 Recruiting Industry
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ …
Sponsor: BioNTech SE
NCT ID: NCT04534205
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following tre…
Sponsor: Daiichi Sankyo
NCT ID: NCT06644781
Sites in Texas: - John Peter Smith Hospital — Fort Worth, Texas
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
- MD Anderson in The Woodlands — Conroe, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- University of Texas Medical Branch — Galveston, Texas
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Cook Children's Medical Center — Fort Worth, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- UT MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Texas: - New Experimental Therapeutics - NEXT Oncology — Austin, Texas
- Texas Oncology — Bedford, Texas
- UT Southwest Simmons Cancer Center — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Texas: - Texas Oncology — Dallas, Texas
- Oncology Consultants — Houston, Texas
- Texas Oncology — Tyler, Texas
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Texas: - Sarah Cannon Research Institute at Mary Crowley — Dallas, Texas
- Renovatio Clinical - El Paso — El Paso, Texas
- NEXT Oncology — San Antonio, Texas
- Renovatio Clinical — The Woodlands, Texas
- The University of Texas Health Science Center at Tyler — Tyler, Texas
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology - DFW — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Texas: - M.D. Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Texas: - NEXT Oncology - Dallas — Dallas, Texas
- START San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Texas: - Houston Methodist Hospital — Houston, Texas
Phase 2 Recruiting Industry
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expr…
Sponsor: AstraZeneca
NCT ID: NCT04379596
Sites in Texas: - Research Site — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Sponsor: Ensem Therapeutics
NCT ID: NCT06993844
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
- START — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT06526819
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of partici…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06469944
Sites in Texas: - University of Texas MD Anderson Cancer Center ( Site 6920) — Houston, Texas
Phase 2 Recruiting Academic/Other
This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients' mouth and cover patients…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04870762
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas